Share Name Share Symbol Market Type Share ISIN Share Description
Lombard Medical Technologies LSE:LMT London Ordinary Share GB00B7FT8W85 ORD 20P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 188.50p 0.00p 0.00p - - - 0.00 05:00:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 7.0 -20.3 -53.5 - 84.34

Lombard Medical Technologies Share Discussion Threads

Showing 2001 to 2022 of 2025 messages
Chat Pages: 81  80  79  78  77  76  75  74  73  72  71  70  Older
DateSubjectAuthorDiscuss
21/5/2014
06:43
Stable, there is a new thread with the Nasdaq ticker here.
skinny
20/5/2014
20:27
today 7.75 bid 8 offered Not good but better than previous info
stable
20/5/2014
12:10
Yesterday the stock traded at 6,44$ or 98p in old money. So some 50% down in a few weeks ???
multiplural
16/5/2014
12:36
now 22% lower than the IPO - £1.25 old money. Far too cheap - maybe one of the big boys will mop it up. The old shareholders like Invesco must be fuming...
baa
03/5/2014
05:45
That was June 2004 following an acquisition spree of small US companies. Bookham was a major casualty of the dotcom bubble. Was its failure down to Nasdaq or its US acquisitions or its management? Friday 25 June 2004 Bookham Technologies, one of the highest profile casualties of the dotcom bubble, has announced plans to abandon its primary London listing and move its corporate head office to Delaware. The move comes at the end of a series of acquisitions which has transformed the company into a broad-based optical components supplier with a strong presence in the United States.
nod
03/5/2014
05:26
Do you remember Bookham , and what it did to the share price when they listed in the US , total destruction, this is dooooomed!
jotoha2
03/5/2014
04:59
I had a go at creating a new thread with Nasdaq Charts and EVAR News but the standard charts and News are not displaying. I have pasted charts instead. http://uk.advfn.com/cmn/fbb/thread.php3?id=31890948
nod
01/5/2014
11:15
NASDAQ Welcomes Lombard Medical Technologies, Inc. (NASDAQ: EVAR) to The NASDAQ Stock Market
skinny
30/4/2014
08:43
At 10$ in the US you actually buy at 1.48 £ . With one for four that prices an old stock at 2,5 $ or some 1,48 £ . Seems to be a very good buying opportunity, especially considering that newly issued shares was at 11$ or £ 1,63 .
multiplural
30/4/2014
06:02
Result of Court Hearing London, UK, 29 April, 2014 - On 26 February 2014, Lombard Medical (AIM: LMT), the specialist medical device company focused on Endovascular Aortic Repair of abdominal aortic aneurysms, announced that it had published a circular which set out the Board of Directors' recommendations to, inter alia, reorganise the Lombard Medical Group pursuant to a Court approved scheme of arrangement (the "Scheme") so that Lombard Medical becomes a directly-owned subsidiary of Lombard Medical, Inc ("LM, Inc"). The Court Hearing, adjourned from 14 April 2014, was held today and the Scheme has been approved. On 25 April 2014 the Company announced the suspension of the Company's shares from trading on AIM. In addition, on the 25 April, LM, Inc. announced the pricing of the IPO of LM, Inc shares on the NASDAQ Global Market. LM, Inc shares commenced trading on the NASDAQ Global Market on 25 April. The Scheme is expected to become effective tomorrow morning, 30 April 2014, following delivery of the Court Order to the Registrar of Companies for registration. At 7.00 a.m. BST (2.00 a.m. ET) tomorrow shares in Lombard Medical, will be cancelled on AIM. This press release and the information it contains is not for publication or distribution, directly or indirectly, in or into the United States. This press release is not intended to, and does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. -Ends-
skinny
25/4/2014
19:50
Complaints to: Canaccord Genuity Limited (Nomad) Tel: +44 (0)20 7523 8000 Lucy Tilley / Tim Redfern / Henry Fitzgerald O'Connor / Dr Julian Feneley FTI Consulting (UK) Tel: +44 (0) 203 727 1000 Simon Conway / Stephanie Cuthbert / Victoria Foster Mitchell
nod
25/4/2014
19:48
1.60 takes LMT (EVAR) back to its 12 month low. This is now a huge 30% to 40% below the original price range set by the advisors. Markets have not fallen anything like 30%~40% so the low price is not down to the market falling.This listing was a mess. The advisors were poor throughout. It looks like they gave LMT an inflated price to get the listing on their books. Like dodgy estate agents. Once again, the only winners have been the financial advisors.What has been the cost of this listing?This will appear in the Final Results as exceptionals but it is real money gone.Hopefully in the long run Nasdaq will be a better place for remaining shareholders. It may take a year or two though.
nod
25/4/2014
15:06
trading at $10.30 or £1.60 old money. management destruction of shareholder value
baa
25/4/2014
07:42
Suspension of trading on AIM London, UK, 25 April, 2014- On 26 February 2014, Lombard Medical (AIM: LMT), the specialist medical device company focused on Endovascular Aortic Repair of abdominal aortic aneurysms, announced that it had published a circular which set out the Board of Directors' recommendations to, inter alia, reorganise the Lombard Medical Technologies Group pursuant to a Court approved scheme of arrangement (the "Scheme") so that Lombard Medical becomes a directly-owned subsidiary of Lombard Medical, Inc ("LM, Inc"). Earlier today, LM, Inc. announced the pricing of the initial public offering on the NASDAQ Global Market of 5,000,000 ordinary shares at a price to the public of $11 per share, raising $55 million. In addition, LM, Inc. has granted the underwriters a 30-day option to purchase up to an additional 750,000 ordinary shares from LM, Inc. Ahead of the Court Hearing to approve the Scheme, scheduled to take place on Tuesday 29 April 2014, shares in the Company will be suspended from trading on AIM from 7.30 a.m. BST today. Following Court approval, the Scheme is expected to become effective on 30 April 2014 and trading in shares in the Company will be cancelled on AIM at 7.00 a.m. BST (2.00 a.m. ET). Shares in LM, Inc. are expected to commence trading on the NASDAQ Global Market at 2.30 p.m. BST (9.30 a.m. ET) on 30 April 2014. This press release and the information it contains is not for publication or distribution, directly or indirectly, in or into the United States. This press release is not intended to, and does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. -Ends-
skinny
23/4/2014
21:02
Lombard Medical, which offers innovative stent-grafts for highly angled endovascular aortic repair, revived plans for its upcoming IPO and lowered the proposed deal size on Wednesday. The Oxfordshire, United Kingdom-based company postponed its IPO in early April but now plans to raise $55 million by offering 5.0 million shares at $11. The company had previously filed to offer 3.6 million shares at a range of $15 to $18. At the midpoint of the revised range, Lombard will raise 8% less in proceeds than previously anticipated. Lombard Medical, which was founded in 2003 and booked $7 million in sales for the fiscal year ended December 31, 2013, plans to list on the NASDAQ under the symbol EVAR. It initially filed confidentially on January 22, 2014. Jefferies and Barclays are the joint bookrunners on the deal. It is expected to price on April 24, 2014 . Read more: http://www.nasdaq.com/article/stent-developer-lombard-medical-revives-ipo-plans-and-decreases-deal-size-cm346620#ixzz2zkIAo67L
25october1969
23/4/2014
09:35
For interest a new journal article. Ovation stent is a Trivascular device. Trivascular have just listed on NASDAQ with ticker TRIV Technical Challenges Encountered During Deployment of the Ovation Abdominal Aortic Stent-Graft System hxxp://jevtonline.org/doi/abs/10.1583/13-4515MR.1
2bob
19/4/2014
20:57
Lombard is still planning to "to push ahead with the Nasdaq listing". http://www.fiercebiotech.com/story/nasdaq-volatility-delays-ipo-almirall-pulls-drug-over-price-topotarget-merg/2014-04-18#ixzz2zMs7hOiF
orange1
15/4/2014
06:09
Lombard Medical Technologies PLC Adjournment of Court Hearing I've just noticed that my shares seem to have disappeared from my SIPP!
skinny
11/4/2014
06:48
What a bloody shambles. No regard for the people who own the company, many of whom have been forced out of their ownership (whose whose brokers do not offer Nasdaq trading) and now this US IPO looks to be on ice for an indefinite period. Why do the board think this is ok? They could have done a dual listing which would have kept everyone on board....
nigelsom
11/4/2014
06:17
Hmmmm - Revision to timetable for recommended Proposal
skinny
10/4/2014
11:40
What a shame that the shares are being de-listed tomorrow. Thursdays won´t be the same without hearing news that a director has transfered err ...... one share.
orange1
07/4/2014
15:27
Small World TriVascular Technologies, which develops new stent grafts for endovascular aortic repair ( EVAR ), announced terms for its IPO on Thursday. The Santa Rosa, CA-based company plans to raise $91 million by offering 6.5 million shares at a price range of $13 to $15. At the midpoint of the proposed range, it would command a fully diluted market value of $284 million. TriVascular Technologies, which was founded in 1998 and booked $20 million in sales for the fiscal year ended December 31, 2013, plans to list on the NASDAQ under the symbol TRIV. It initially filed confidentially on December 16, 2013. J.P. Morgan and Credit Suisse are the joint bookrunners on the deal. Read more: http://www.nasdaq.com/article/stent-developer-trivascular-technologies-sets-terms-for-91-million-ipo-cm341255#ixzz2yDLxxCZk
25october1969
Chat Pages: 81  80  79  78  77  76  75  74  73  72  71  70  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20161208 14:04:39